Doster, Dominique L.Jensen, Amanda R.Khaneki, SinaMarkel, Troy A.2018-06-082018-06-082016-12Doster, D. L., Jensen, A. R., Khaneki, S., & Markel, T. A. (2016). Mesenchymal Stromal Cell Therapy for the Treatment of Intestinal Ischemia: Defining the Optimal Cell Isolate for Maximum Therapeutic Benefit. Cytotherapy, 18(12), 1457–1470. https://doi.org/10.1016/j.jcyt.2016.08.0011465-3249https://hdl.handle.net/1805/16458Intestinal ischemia is a devastating intraabdominal emergency that often necessitates surgical intervention. Mortality rates can be high, and patients who survive often have significant long-term morbidity. The implementation of traditional medical therapies to prevent or treat intestinal ischemia have been sparse over the last decade, and therefore, the use of novel therapies are becoming more prevalent. Cellular therapy using mesenchymal stromal cells is one such treatment modality that is attracting noteworthy attention in the scientific community. Several groups have seen benefit with cellular therapy, but the optimal cell line has not been identified. The purpose of this review is to: 1) Review the mechanism of intestinal ischemia and reperfusion injury, 2) Identify the mechanisms of how cellular therapy may be therapeutic for this disease, and 3) Compare various MSC tissue sources to maximize potential therapeutic efficacy in the treatment of intestinal I/R diseases.en-USPublisher PolicyMesenchymal stromal cellintestinal ischemianecrotizing enterocolitiscellular therapyArticle